Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dronabinol for Agitation in Alzheimer's Disease
NCT07422311Phase 3Not yet recruiting
- Sponsor
- Benuvia
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dronabinol in Alzheimer's disease (AD), sponsored by Benuvia. Planned start May 2026; status: not yet recruiting.
02
Drugs
dronabinol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07422311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07422311.